IPH5201 + durvalumab + standard chemotherapy for Non-Small Cell Lung Cancer

Phase-Based Progress Estimates
Gustave Roussy, Villejuif, FranceNon-Small Cell Lung CancerIPH5201 + durvalumab + standard chemotherapy - Drug
All Sexes
What conditions do you have?

Study Summary

This trial will test a combo of drugs for early-stage NSCLC to see if it can safely and effectively treat the disease.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 8 Secondary · Reporting Duration: Up to approximately 2 years.

Week 16
Pathological Complete Response (pCR)
Week 16
Major Pathological Response (mPR)
Surgical resection
Day 90
Adverse events (AEs) and serious adverse events (SAEs)
Year 2
Disease Free Survival (DFS)
Event-Free Survival (EFS)
Overall Survival (OS)
Month 4
Anti-study drug antibodies (ADA)
Objective Response Rate (ORR)
PK of IPH5201 in combination with durvalumab +/- chemotherapy

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

IPH5201 + durvalumab + standard chemotherapy
1 of 1

Experimental Treatment

70 Total Participants · 1 Treatment Group

Primary Treatment: IPH5201 + durvalumab + standard chemotherapy · No Placebo Group · Phase 2

IPH5201 + durvalumab + standard chemotherapy
Experimental Group · 1 Intervention: IPH5201 + durvalumab + standard chemotherapy · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to approximately 2 years.

Who is running the clinical trial?

Innate PharmaLead Sponsor
26 Previous Clinical Trials
2,842 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

How many participants are being included in the research endeavor?

"Affirmative. The details provided on clinicaltrials.gov verify that this research trial, which was first publicized in February 1st 2023, is actively soliciting participants. Approximately 70 subjects must be enlisted from two distinct centres of care." - Anonymous Online Contributor

Unverified Answer

Is this research initiative currently accepting new participants?

"According to the clinicaltrials.gov website, this medical trial is currently open for enrollment and was initially announced on February 1st 2023 with its last update taking place on February 23rd of that same year." - Anonymous Online Contributor

Unverified Answer

Has the combination of IPH5201, durvalumab and standard chemotherapy been endorsed by the FDA?

"Our team's evaluation graded the safety of IPH5201 + durvalumab + standard chemotherapy at 2 out of 3 due to only Phase 2 trial results being available and no existing evidence for efficacy." - Anonymous Online Contributor

Unverified Answer

What are the distinct ambitions of this clinical trial?

"Innate Pharma, the trial sponsor of this medical study, has indicated that Adverse events (AEs) and Serious adverse Events (SAEs) will be measured as primary outcomes over a 16 week period post-first dose. Additionally, Disease Free Survival (DFS), Surgical Resection, and Anti-study Drug Antibodies (ADA) are noted as secondary outcomes for measurement purposes." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.